GSK plc (GSK) Financial Ratios
30 years of historical data (1996–2025) · Healthcare · Drug Manufacturers - General
EV/EBITDA
↓
8.34
↓-24% vs avg
5yr avg: 10.98
30Y Low6.1·High93.1
P/FCF
↓
12.80
-1% vs avg
5yr avg: 12.91
30Y Low8.7·High199.8
P/B Ratio
↑
2.40
↓-47% vs avg
5yr avg: 4.55
30Y Low2.5·High73.0
ROE
↑
39.4%
↓+6% vs avg
5yr avg: 37.2%
30Y Low13%·High268%
Debt/EBITDA
↓
1.66
↓-42% vs avg
5yr avg: 2.86
30Y Low0.6·High5.1
Percentile shows where the current value sits in 30-year historical distribution. Sparklines show 5-year trend.
GSK Valuation Multiples
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
GSK plc trades at 6.7x earnings, 60% below its 5-year average of 16.5x, sitting at the 0th percentile of its historical range. Compared to the Healthcare sector median P/E of 22.2x, the stock trades at a discount of 70%. On a free-cash-flow basis, the stock trades at 12.8x P/FCF, roughly in line with the 5-year average of 12.9x.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $101.3B | $50.5B | $70.0B | $76.2B | $71.8B | $71.5B | $74.2B | $94.3B | $76.0B | $70.1B | $75.6B |
| Enterprise Value | $120.7B | $64.8B | $83.3B | $95.4B | $89.0B | $98.4B | $102.7B | $128.5B | $98.2B | $83.4B | $89.5B |
| P/E Ratio → | 6.67 | 8.82 | 27.27 | 15.44 | 14.64 | 16.33 | 12.87 | 20.25 | 20.99 | 45.47 | 83.72 |
| P/S Ratio | 2.28 | 1.55 | 2.23 | 2.51 | 2.45 | 2.89 | 3.05 | 2.79 | 2.47 | 2.32 | 2.71 |
| P/B Ratio | 2.40 | 3.17 | 5.35 | 4.67 | 7.11 | 2.47 | 2.61 | 3.88 | 20.69 | 20.09 | 15.24 |
| P/FCF | 12.80 | 8.67 | 19.61 | 12.17 | 10.63 | 13.49 | 11.42 | 16.10 | 11.47 | 14.86 | 18.24 |
| P/OCF | 10.44 | 7.07 | 10.69 | 9.65 | 8.79 | 8.99 | 8.79 | 11.76 | 9.02 | 10.13 | 11.64 |
P/E links to full P/E history page with 30-year chart
GSK EV Ratios
Enterprise-value multiples — capital-structure-neutral measures of total business value
GSK plc's enterprise value stands at 8.3x EBITDA, 24% below its 5-year average of 11.0x. The Healthcare sector median is 14.0x, placing the stock at a 41% discount on an enterprise-value basis.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 1.98 | 2.66 | 3.15 | 3.04 | 3.99 | 4.22 | 3.81 | 3.19 | 2.76 | 3.21 |
| EV / EBITDA | 8.34 | 6.08 | 12.68 | 10.55 | 10.38 | 15.19 | 12.79 | 14.15 | 13.38 | 13.87 | 20.47 |
| EV / EBIT | 10.66 | 8.01 | 20.24 | 14.05 | 13.79 | 22.56 | 17.06 | 18.09 | 17.87 | 19.56 | 33.70 |
| EV / FCF | — | 11.12 | 23.33 | 15.25 | 13.18 | 18.58 | 15.81 | 21.93 | 14.82 | 17.68 | 21.59 |
GSK Profitability
Margins and return-on-capital ratios measuring operating efficiency
GSK plc earns an operating margin of 25.5%. Operating margins have expanded from 22.2% to 25.5% over the past 3 years, signaling improving operational efficiency. Return on equity of 39.4% is exceptionally high. ROIC of 22.1% represents excellent returns on invested capital.
Margins
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 72.4% | 72.4% | 71.2% | 71.8% | 67.4% | 66.9% | 67.4% | 64.9% | 66.8% | 65.7% | 66.7% |
| Operating Margin | 25.5% | 25.5% | 12.8% | 22.2% | 21.9% | 17.6% | 24.6% | 20.6% | 17.8% | 13.5% | 9.3% |
| Net Profit Margin | 17.5% | 17.5% | 8.2% | 16.2% | 51.0% | 17.8% | 23.6% | 13.8% | 11.8% | 5.1% | 3.3% |
Return on Capital
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 39.4% | 39.4% | 17.5% | 37.3% | 76.7% | 15.3% | 21.8% | 33.2% | 101.2% | 36.3% | 13.2% |
| ROA | 9.5% | 9.5% | 3.8% | 7.3% | 17.9% | 4.0% | 5.3% | 5.7% | 6.3% | 2.7% | 1.6% |
| ROIC | 22.1% | 22.1% | 9.7% | 16.1% | 11.6% | 5.8% | 7.8% | 12.4% | 19.3% | 17.2% | 10.1% |
| ROCE | 21.5% | 21.5% | 9.3% | 15.7% | 11.4% | 5.6% | 7.8% | 12.7% | 16.8% | 11.7% | 6.5% |
GSK Leverage & Debt
Solvency and debt-coverage ratios — lower is generally safer
GSK plc carries a Debt/EBITDA ratio of 1.7x, which is manageable (47% below the sector average of 3.1x). Net debt stands at $14.3B ($17.7B total debt minus $3.4B cash). Interest coverage of 11.8x signals virtually no risk of debt distress — earnings comfortably cover interest obligations.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 1.11 | 1.11 | 1.30 | 1.41 | 2.08 | 1.13 | 1.30 | 1.66 | 7.10 | 4.90 | 3.79 |
| Debt / EBITDA | 1.66 | 1.66 | 2.58 | 2.54 | 2.45 | 5.05 | 4.62 | 4.45 | 3.55 | 2.84 | 4.30 |
| Net Debt / Equity | — | 0.90 | 1.02 | 1.18 | 1.71 | 0.93 | 1.00 | 1.41 | 6.04 | 3.80 | 2.80 |
| Net Debt / EBITDA | 1.34 | 1.34 | 2.02 | 2.13 | 2.01 | 4.16 | 3.55 | 3.76 | 3.02 | 2.21 | 3.18 |
| Debt / FCF | — | 2.45 | 3.72 | 3.07 | 2.56 | 5.09 | 4.39 | 5.84 | 3.35 | 2.81 | 3.35 |
| Interest Coverage | 11.77 | 11.77 | 6.26 | 8.76 | 7.54 | 5.57 | 6.75 | 7.79 | 7.39 | 5.81 | 3.61 |
GSK Liquidity & Efficiency
Short-term solvency ratios and asset-utilisation metrics
The current ratio of 0.82x is below 1.0, meaning current liabilities exceed current assets — though the company's $3.4B cash position helps mitigate short-term liquidity concerns. The current ratio has declined from 0.88x to 0.82x over the past 3 years.
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 0.82 | 0.82 | 0.78 | 0.88 | 0.91 | 0.79 | 0.91 | 0.81 | 0.75 | 0.60 | 0.88 |
| Quick Ratio | 0.54 | 0.54 | 0.52 | 0.62 | 0.68 | 0.54 | 0.64 | 0.56 | 0.51 | 0.39 | 0.61 |
| Cash Ratio | 0.16 | 0.16 | 0.17 | 0.25 | 0.35 | 0.18 | 0.29 | 0.20 | 0.18 | 0.15 | 0.26 |
| Asset Turnover | — | 0.54 | 0.53 | 0.40 | 0.49 | 0.23 | 0.22 | 0.32 | 0.53 | 0.54 | 0.47 |
| Inventory Turnover | 1.52 | 1.52 | 1.60 | 1.22 | 1.86 | 1.04 | 0.97 | 1.51 | 1.87 | 1.86 | 1.82 |
| Days Sales Outstanding | — | 86.54 | 69.79 | 113.58 | 77.40 | 160.77 | 148.82 | 102.40 | 74.87 | 68.83 | 74.48 |
GSK Shareholder Yields
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
GSK plc returns 6.6% to shareholders annually primarily through dividends. A payout ratio of 43.9% is moderate and appears sustainable, balancing shareholder returns with reinvestment capacity. The earnings yield of 15.0% (inverse of P/E) provides a useful comparison to bond yields when assessing the stock's relative attractiveness to fixed income.
Dividends
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | 6.6% | 5.0% | 3.5% | 3.7% | 6.0% | 5.6% | 5.4% | 4.2% | 5.2% | 5.6% | 6.4% |
| Payout Ratio | 43.9% | 43.9% | 94.9% | 56.7% | 28.6% | 91.2% | 69.2% | 85.1% | 108.4% | 255.0% | 531.8% |
Total Shareholder Return Metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | 15.0% | 11.3% | 3.7% | 6.5% | 6.8% | 6.1% | 7.8% | 4.9% | 4.8% | 2.2% | 1.2% |
| FCF Yield | 7.8% | 11.5% | 5.1% | 8.2% | 9.4% | 7.4% | 8.8% | 6.2% | 8.7% | 6.7% | 5.5% |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.1% | 0.1% |
| Total Shareholder Yield | 6.6% | 5.0% | 3.5% | 3.7% | 6.0% | 5.6% | 5.4% | 4.2% | 5.2% | 5.7% | 6.5% |
| Shares Outstanding | — | $1.0B | $2.1B | $2.1B | $2.0B | $1.6B | $2.0B | $2.0B | $2.0B | $2.0B | $2.0B |
Peer Comparison
Compare GSK with 10 similar companies in its peer group
| Company | Market Cap | P/E | EV/EBITDA | P/FCF | Gross Margin | Op Margin | ROE | ROIC | Debt/EBITDA |
|---|---|---|---|---|---|---|---|---|---|
 GSKYou | $101B | 6.7 | 8.3 | 12.8 | 72.4% | 25.5% | 39.4% | 22.1% | 1.7 |
 AZN | $281B | 27.7 | 15.7 | 23.9 | 81.9% | 23.4% | 22.9% | 14.9% | 1.5 |
 NVS | $278B | 20.2 | 13.5 | 15.7 | 75.0% | 31.2% | 31.0% | 18.8% | 1.7 |
 SNY | $105B | 18.2 | 10.8 | 10.0 | 72.3% | 13.6% | 10.4% | 5.5% | 2.3 |
 PFE | $150B | 19.4 | 10.7 | 16.6 | 70.3% | 24.7% | 8.9% | 7.5% | 3.3 |
 MRK | $279B | 15.5 | 10.8 | 22.6 | 72.0% | 36.2% | 36.9% | 22.0% | 1.7 |
 BMY | $116B | 16.5 | 9.3 | 9.0 | 67.6% | 26.3% | 40.4% | 16.9% | 2.8 |
 LLY | $934B | 43.1 | 31.0 | 104.1 | 83.8% | 45.6% | 101.2% | 41.8% | 1.4 |
 ABBV | $365B | 87.0 | 15.2 | 20.5 | 70.2% | 32.8% | 6214.7% | 23.9% | 2.4 |
 JNJ | $544B | 39.0 | 18.9 | 27.4 | 69.1% | 24.9% | 20.1% | 20.7% | 1.2 |
 HLN | $41B | 18.7 | 13.5 | 15.2 | 64.8% | 22.4% | 10.0% | 7.6% | 3.1 |
| Healthcare Median | — | 22.2 | 14.0 | 18.6 | 64.1% | -5.3% | -34.0% | -11.2% | 3.1 |
Peer selection based on competitive and market overlap. Compare multiple stocks →
Download Financial Ratios Data
Includes 30+ ratios · 30 years · Updated daily
Full GSK Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
See GSK's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GSK Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GSK vs AZN
Side-by-side business, growth, and profitability comparison vs AstraZeneca PLC.
Start ComparisonGSK — Frequently Asked Questions
Quick answers to the most common questions about buying GSK stock.
What is GSK plc's P/E ratio?
GSK plc's current P/E ratio is 6.7x. The historical average is 27.3x.
What is GSK plc's EV/EBITDA?
GSK plc's current EV/EBITDA is 8.3x. This enterprise value multiple compares the company's total value (equity + debt - cash) to its EBITDA. The historical average is 21.1x.
What is GSK plc's ROE?
GSK plc's return on equity (ROE) is 39.4%. This is above the typical threshold of 15-20% considered good for most companies. The historical average is 61.5%.
Is GSK stock overvalued?
Based on historical data, GSK plc is trading at a P/E of 6.7x. Compare with industry peers and growth rates for a complete picture.
What is GSK plc's dividend yield?
GSK plc's current dividend yield is 6.57% with a payout ratio of 43.9%.
What are GSK plc's profit margins?
GSK plc has 72.4% gross margin and 25.5% operating margin. Operating margin above 20% indicates strong pricing power and cost efficiency.
How much debt does GSK plc have?
GSK plc's Debt/EBITDA ratio is 1.7x, indicating moderate leverage. A ratio below 2x is generally considered financially healthy.